The Impact of 2013 ASCO/CAP Guidelines on the Practice of HER2 Testing in a Reference Laboratory

被引：0
|
作者：
Hanna, Wedad [1 ]
Slodkowska, Elzbieta [1 ]
Lu, Fang-I [1 ]
Han, Guangming [1 ]
Nafisi, Houman [1 ]
Nofech-Mozes, Sharon [1 ]
机构：
[1] Univ Toronto, SHSC, Toronto, ON, Canada
来源：
LABORATORY INVESTIGATION | 2016年 / 96卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
167
引用
收藏
页码：44A / 44A
页数：1
相关论文
共 50 条
  • [31] Adherence to ASCO/CAP HER2 Testing Guidelines: Equivocal Rates and Impact on Management within a Single Institution
    Portier, B. P.
    Downs-Kelly, E.
    Lanigan, C.
    Cotta, C.
    Patil, D.
    Procop, G.
    Cook, J. R.
    Moore, H.
    Budd, G. T.
    Tubbs, R. R.
    MODERN PATHOLOGY, 2011, 24 : 436A - 436A
  • [32] HER2 testing in breast cancers: Comparison of Assays and Interpretation Using ASCO-CAP 2013 with 2018 guidelines
    Mclemore, Lauren
    Albarracin, Constance
    Chen, Hui
    Bassett, Roland
    Dhamne, Sagar
    Gruschkus, Stephen
    Yim, Isaiah
    Lin, Kevin
    Wu, Yun
    LABORATORY INVESTIGATION, 2019, 99
  • [33] Impact of the 2013 ASCO/CAP HER2 revised guidelines on HER2 results in breast core biopsies with invasive breast carcinoma: a retrospective study
    Wynton B. Overcast
    Jianying Zhang
    Debra L. Zynger
    Gary H. Tozbikian
    Virchows Archiv, 2016, 469 : 203 - 212
  • [34] Impact of the 2013 ASCO/CAP HER2 revised guidelines on HER2 results in breast core biopsies with invasive breast carcinoma: a retrospective study
    Overcast, Wynton B.
    Zhang, Jianying
    Zynger, Debra L.
    Tozbikian, Gary H.
    VIRCHOWS ARCHIV, 2016, 469 (02) : 203 - 212
  • [35] Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer
    Lei Guo
    Pei Yuan
    Jing Zhang
    Yun Ling
    Wenbin Li
    Bohui Zhao
    Jianming Ying
    Lixue Xuan
    Breast Cancer Research and Treatment, 2017, 166 : 77 - 84
  • [36] Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer
    Guo, Lei
    Yuan, Pei
    Zhang, Jing
    Ling, Yun
    Li, Wenbin
    Zhao, Bohui
    Ying, Jianming
    Xuan, Lixue
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 166 (01) : 77 - 84
  • [37] Application of the ASCO/CAP guidelines for HER2 testing to mRNA expression values from microarrays
    Shaye, A. N.
    Gong, Y.
    Yan, K.
    Sneige, N.
    Esteva, F. J.
    Hortobagyi, G. N.
    Pusztai, L.
    Symmans, W. F.
    LABORATORY INVESTIGATION, 2008, 88 : 54A - 54A
  • [38] Application of the ASCO/CAP guidelines for HER2 testing to mRNA expression values from microarrays
    Shaye, A. N.
    Gong, Y.
    Sneige, N.
    Esteva, F. J.
    Hortobagyu, G. N.
    Pusztai, L.
    Symmans, W. F.
    MODERN PATHOLOGY, 2008, 21 : 54A - 54A
  • [39] HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline
    Yao-Shan Fan
    Carmen E. Casas
    Jinghong Peng
    Melanie Watkins
    Lynn Fan
    Jennifer Chapman
    Offiong Francis Ikpatt
    Carmen Gomez
    Wei Zhao
    Isildinha M. Reis
    Breast Cancer Research and Treatment, 2016, 155 : 457 - 462
  • [40] HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline
    Fan, Yao-Shan
    Casas, Carmen E.
    Peng, Jinghong
    Watkins, Melanie
    Fan, Lynn
    Chapman, Jennifer
    Ikpatt, Offiong Francis
    Gomez, Carmen
    Zhao, Wei
    Reis, Isildinha M.
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 155 (03) : 457 - 462
12345